



2021 NTM Research Consortium Meeting

Thursday, November 11, 2021

Agenda

HOR D'OEUVRES

3:00pm-3:30pm

- 3:30pm – 3:45pm **Welcome, Introductions and Meetings Objectives**
Kevin Winthrop, Oregon Health & Science University
- 3:45pm – 6:45pm **NTM Consortium Site Updates**
- 3:45pm **University Health Network** (Ted Marras)
- 4:30pm **Oregon Health & Science University** (Kevin Winthrop)
- 5:15pm **National Institute of Allergy and Infectious Diseases**
(Rebecca Prevots, Emily Matlock, Alyssa Meyer, Alex Rosenthal)
- 6:00pm **National Jewish Health** (Charles Daley)

BUFFET DINNER

6:30pm

- 7:00pm – 8:00pm **Keynote Address**
- 7:00pm **Philip Mehler**, ACUTE at Denver Health
Eating Disorders and NTM...or Not: Medical Complications of Anorexia Nervosa and Bulimia
Q&A

DESSERT & NETWORKING



2021 NTM Research Consortium Meeting

Friday, November 12, 2021

Agenda

CONTINENTAL BREAKFAST

8:00am-8:30am

- 8:30am – 8:40am **Welcome, Introductions, and Meeting Objectives**
Kevin Winthrop, Oregon Health & Science University
- 8:40am – 12:15pm **Non-Antimicrobial Approaches to NTM**
- 8:40am **Kenneth Olivier**, National Heart, Lung, and Blood Institute
Non-Antimicrobial Approaches to NTM
Q&A
- 9:15am **Charles Haworth**, Cambridge Centre for Lung Infection, University of Cambridge
Brensocatic and Other Therapies for Bronchiectasis – Do they have a role in NTM?
Q&A
- 9:50am **Anne O’Donnell**, Georgetown University
Airway Clearance and Hygiene
Q&A

Break

10:25am-10:35am

- 10:35am **Patrick Flume**, Medical University of South Carolina
Nitric Oxide and its Therapeutic Potential
Q&A
- 11:10am **Luis Bermudez**, Oregon State University College of Agricultural Sciences & College of Science
Potential Therapeutic Strategies Targeting NTM in the Lung Environment
Q&A
- 11:45am **Ilhem Messaoudi**, Microbiology and Immunology, University of Kentucky College of Medicine
Advanced Age Exacerbates M. avium Pulmonary Disease in Macaques
Q&A

Lunch

12:15pm-1:15pm



2021 NTM Research Consortium Meeting

Friday, November 12, 2021

1:15pm-3:50pm

Therapeutic Development with Focus on *M. abscessus*

1:15pm

Shannon Kasperbauer & David Griffith, National Jewish Health
Trial Design in Mycobacterium abscessus
Q&A

1:55pm

Emily Henkle, Oregon Health & Science University
PRO Development in MAC – Does it translate to M. abscessus?
Q&A

2:30pm

Keira Cohen, Johns Hopkins Medicine
Phage Therapy for NTM
Q&A

3:10pm

Rachel Thomson, The University of Queensland
GM-CSF Therapy, Development and Current State of M. abscessus Trials in Australia
Q&A

Break

3:50pm-4:00pm

4:00pm-4:30pm

Q&A / Discussion / Goal Setting

4:30pm-5:30pm

What's Cooking in Industry's Corner

What's Cooking in Industry's Corner

4:30pm

Paul Eckburg, Chief Medical Officer, AN2 Therapeutics, Inc.

4:45pm

Kevin Mange, SVP, Head of Clinical Development, Insmad Incorporated

5:00pm

Dan Deck, Director, Medical Science, Paratek Pharmaceuticals

5:15pm

Mark Schoenfisch, Co-Founder and CSO, Vast Therapeutics

Dinner

6:15pm-8:00pm